Pfizer Methotrexate Injection 1 g

Adult dosage

1. Leukemia: Administer 5～10 mg of methotrexate orally per day for 3～6 days per week. 2. Trophoblastic disease: Administer 10～30 mg orally per day. Use a 5-day treatment cycle, and repeat after a drug-free period of 7～12 days. 3. Rheumatoid arthritis: Administer a test dose of 5～10 mg orally once, 1 week before treatment. Administer 7.5～20 mg orally once weekly, or administer 2.5 mg orally 3 times at 12-hour intervals. The total weekly dose should not exceed 20 mg. 4. Psoriasis: Administer a test dose of 5～10 mg orally once, 1 week before treatment. Administer 7.5～20 mg orally once weekly or orally in 3 divided doses at 12-hour intervals. Injectable formulation: 1) Trophoblastic disease: Use a 5-day treatment cycle and administer 10～30 ㎎/㎡ per day by intramuscular injection for 5 days. Allow a drug-free period of 7～12 days. The cycle may be repeated 3～5 times. 2) Breast cancer: Administer 10～60 ㎎/㎡ intravenously. 3) Lung cancer: Administer 20～100 ㎎/㎡ by intravenous infusion or injection. 4) Head and neck cancer: Administer 240～1,080 ㎎/㎡ by intravenous infusion, followed by leucovorin calcium rescue therapy. 5) Bladder cancer: Administer up to 100 mg intravenously by injection or infusion every 1 or 2 weeks. 6) Osteosarcoma: Administer 600～9,000 ㎎/㎡ by intravenous infusion, followed by leucovorin calcium rescue therapy. 7) Non-Hodgkin lymphoma: Administer 90～900 ㎎/㎡ by intravenous injection or infusion, followed by high-dose leucovorin calcium. Administration for psoriasis: Administer a test dose of 5～10 mg orally once, 1 week before treatment. For severe, uncontrolled psoriasis refractory to existing therapy, administer 10～25 ㎎ orally once weekly or by intravenous or intramuscular injection. Adjust the dose according to the patient's response.

Children's dosage

1. Leukemia: Administer methotrexate 1.25～2.5 mg per day to infants and 2.5～5 mg per day to children orally for 3～6 days per week. Injectable formulation: 1) Meningeal leukemia in children: Administer 12～15 ㎎/㎡ (0.4～0.5 ㎎ per kg) by intrathecal injection at 1-week intervals until the cerebrospinal fluid returns to normal.

This medication should be taken only once a week during treatment for rheumatoid arthritis or psoriasis, and the method of administration and dosage must be strictly adhered to in order to prevent serious side effects. Co-administration of this drug with certain chemotherapy drugs poses risks, so treatment must be conducted under the supervision of a physician, and medical facilities prepared for emergencies and experienced doctors are required. Care must be taken when using this drug in high doses with proton pump inhibitors, as its concentration may increase and lead to toxicity. Patients with allergies to this drug's components, or with kidney or liver function issues, pregnant or potentially pregnant women, or nursing mothers should not use this medication. Patients with specific conditions such as diarrhea, mucositis, blood disorders, infections, mental disorders, children, the elderly, etc. should use this drug with caution, and immediate consultation with medical personnel is necessary if abnormal symptoms occur. During administration, various side effects may occur, including allergic reactions, gastrointestinal issues, respiratory problems, neurological abnormalities, reproductive problems, blood disorders, and liver and kidney function decline, so the patient's condition should be monitored frequently. This medication has immunosuppressive effects, so caution against infections is necessary, and care is also required during vaccinations. Taking this drug during pregnancy significantly increases the risk of miscarriage and birth defects, so women who are pregnant or planning to become pregnant should strictly avoid it, and pregnancy should be avoided for at least six months after treatment. Men are also advised to avoid pregnancy during and for six months after taking this medication. This medication should be administered to children and the elderly with greater caution, and liver and kidney function should be tested regularly. Due to interactions when used with other medications, the toxicity of this drug may increase, so if you are taking other medications, you must consult with a physician or pharmacist. In case of overdose, immediate treatment at a medical institution is necessary, and special treatment may be required to reduce the toxicity of this drug. This medication should be stored in a place out of reach of children, not transferred to other containers, and should be used promptly after dilution.

• Shock
• anaphylactic symptoms
• hemorrhagic enteritis
• necrotizing enteritis
• abdominal pain
• diarrhea
• nausea
• vomiting
• stomatitis
• loss of appetite

This medication should be stored in a tightly sealed container to prevent air exposure and kept in a dark place to avoid light exposure. Additionally, it is important to store it at a cool temperature below 25 degrees Celsius to maintain the drug's effectiveness.

Appearance

A clear solution injection contained in a transparent vial with a yellow to orange clear liquid

Package unit

1 g/10mL X 1 vial